CoChat

Smad3 Induces Atrogin-1, Inhibits mTOR and Protein Synthesis, and Promotes Muscle Atrophy In Vivo

Open access
Goodman, Craig A., McNally, Rachel M., Hoffmann, F. Michael, Hornberger, Troy A. · 2013 · Molecular Endocrinology
Cited by 138

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Myostatin, a member of the TGF superfamily, is sufficient to induce skeletal muscle atrophy. Myostatin-induced atrophy is associated with increases in E3-ligase atrogin-1 expression and protein degradation and decreases in Akt/mechanistic target of rapamycin (mTOR) signaling and protein synthesis. Myostatin signaling activates the transcription factor Smad3 (Small Mothers Against Decapentaplegic), which has been shown to be necessary for myostatin-induced atrogin-1 expression and atrophy; however, it is not known whether Smad3 is sufficient to induce these events or whether Smad3 simply plays a permissive role. Thus, the aim of this study was to address these questions with an in vivo model. To accomplish this goal, in vivo transfection of plasmid DNA was used to create transient transgenic mouse skeletal muscles, and our results show for the first time that Smad3 expression is sufficient to stimulate atrogin-1 promoter activity, inhibit Akt/mTOR signaling and protein synthesis, and induce muscle fiber atrophy. Moreover, we propose that Akt/mTOR signaling is inhibited by a Smad3-induced decrease in microRNA-29 (miR-29) expression and a subsequent increase in the translation of phosphatase and tensin homolog (PTEN) mRNA. Smad3 is also sufficient to inhibit peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α) promoter activity and to increase FoxO (Forkhead Box Protein, Subclass O)-mediated signaling and the promoter activity of plasminogen activator inhibitor 1 (PAI-1). Combined, this study provides the first evidence that Smad3 is sufficient to regulate many of the events associated with myostatin-induced atrophy and therefore suggests that Smad3 signaling may be a viable target for therapies aimed at preventing myostatin-induced muscle atrophy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/me.2013-1194

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 59

  1. Goodman, 2011, Recent progress toward understanding the molecular mechanisms that regulate skeletal muscle mass, Cell Signal, 23, 1896, 10.1016/j.cellsig.2011.07.013 · DOI · Paper page
  2. Lynch, 2004, Tackling Australia's future health problems: developing strategies to combat sarcopenia: age-related muscle wasting and weakness, Intern Med J, 34, 294, 10.1111/j.1444-0903.2004.00568.x · DOI · Paper page
  3. Aversa, 2012, Changes in myostatin signaling in non-weight-losing cancer patients, Ann Surg Oncol, 19, 1350, 10.1245/s10434-011-1720-5 · DOI
  4. Léger, 2008, Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation, Rejuvenation Res, 11, 163B, 10.1089/rej.2007.0588 · DOI · Paper page
  5. Bish, 2011, Myostatin is elevated in congenital heart disease and after mechanical unloading, PLoS ONE, 6, e23818, 10.1371/journal.pone.0023818 · DOI
  6. Gustafsson, 2010, Effects of 3 days unloading on molecular regulators of muscle size in humans, J Appl Physiol, 109, 721, 10.1152/japplphysiol.00110.2009 · DOI · Paper page
  7. Ju, 2012, Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease, Respir Med, 106, 102, 10.1016/j.rmed.2011.07.016 · DOI · Paper page
  8. Verzola, 2011, Apoptosis and myostatin mRNA are upregulated in the skeletal muscle of patients with chronic kidney disease, Kidney Int, 79, 773, 10.1038/ki.2010.494 · DOI
  9. Durieux, 2007, Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression, Endocrinology, 148, 3140, 10.1210/en.2006-1500 · DOI · Paper page
  10. Li, 2008, Myostatin Directly Regulates Skeletal Muscle Fibrosis, J Biol Chem, 283, 19371, 10.1074/jbc.M802585200 · DOI · Paper page
  11. Zhu, 2007, Relationships between transforming growth factor-β1, myostatin, and decorin: implications for skeletal muscle fibrosis, J Biol Chem, 282, 25852, 10.1074/jbc.M704146200 · DOI · Paper page
  12. Elkasrawy, 2012, Immunolocalization of myostatin (GDF-8) following musculoskeletal injury and the effects of exogenous myostatin on muscle and bone healing, J Histochem Cytochem, 60, 22, 10.1369/0022155411425389 · DOI
  13. Elkina, 2011, The role of myostatin in muscle wasting: an overview, J Cachexia Sarcopenia Muscle, 2, 143, 10.1007/s13539-011-0035-5 · DOI · Paper page
  14. Walton, 2012, New insights into the mechanisms of activin action and inhibition, Mol Cell Endocrinol, 359, 2, 10.1016/j.mce.2011.06.030 · DOI
  15. Tsuchida, 2008, Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer, Endocr J, 55, 11, 10.1507/endocrj.KR-110 · DOI · Paper page
  16. Mendias, 2012, Transforming growth factor-β induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis, Muscle Nerve, 45, 55, 10.1002/mus.22232 · DOI · Paper page
  17. Ross, 2008, How the Smads regulate transcription, Int J Biochem Cell Biol, 40, 383, 10.1016/j.biocel.2007.09.006 · DOI · Paper page
  18. Lokireddy, 2011, Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting, Mol Endocrinol, 25, 1936, 10.1210/me.2011-1124 · DOI · Paper page
  19. Lokireddy, 2011, Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins, Am J Physiol Cell Physiol, 301, C1316, 10.1152/ajpcell.00114.2011 · DOI · Paper page
  20. Lokireddy, 2012, Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting, Am J Physiol Cell Physiol, 303, C512, 10.1152/ajpcell.00402.2011 · DOI · Paper page
  21. Taylor, 2001, Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells, Am J Physiol Endocrinol Metab, 280, E221, 10.1152/ajpendo.2001.280.2.E221 · DOI · Paper page
  22. Welle, 2006, Myofibrillar protein synthesis in myostatin-deficient mice, Am J Physiol Endocrinol Metab, 290, E409, 10.1152/ajpendo.00433.2005 · DOI · Paper page
  23. Welle, 2009, Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice, Am J Physiol Endocrinol Metab, 296, E567, 10.1152/ajpendo.90862.2008 · DOI · Paper page
  24. Welle, 2011, Effect of postdevelopmental myostatin depletion on myofibrillar protein metabolism, Am J Physiol Endocrinol Metab, 300, E993, 10.1152/ajpendo.00509.2010 · DOI
  25. Rodriguez, 2011, Myostatin inactivation increases myotube size through regulation of translational initiation machinery, J Cell Biochem, 112, 3531, 10.1002/jcb.23280 · DOI · Paper page
  26. Hulmi, 2013, Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins, Am J Physiol Endocrinol Metab, 304, E41, 10.1152/ajpendo.00389.2012 · DOI · Paper page
  27. Lagirand-Cantaloube, 2008, The initiation factor eIF3-f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy, EMBO J, 27, 1266, 10.1038/emboj.2008.52 · DOI · Paper page
  28. Amirouche, 2009, Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle, Endocrinology, 150, 286, 10.1210/en.2008-0959 · DOI · Paper page
  29. Zhou, 2012, Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts, PLoS ONE, 7, e33766, 10.1371/journal.pone.0033766 · DOI
  30. Kong, 2011, Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model, PLoS ONE, 6, e19518, 10.1371/journal.pone.0019518 · DOI · Paper page
  31. Wang, 2011, miR-29b regulates migration of human breast cancer cells, Mol Cell Biochem, 352, 197, 10.1007/s11010-011-0755-z · DOI
  32. Goodman, 2010, A phosphatidylinositol 3-kinase/protein kinase B-independent activation of mammalian target of rapamycin signaling is sufficient to induce skeletal muscle hypertrophy, Mol Biol Cell, 21, 3258, 10.1091/mbc.e10-05-0454 · DOI · Paper page
  33. Goodman, 2011, Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique, FASEB J, 25, 1028, 10.1096/fj.10-168799 · DOI · Paper page
  34. Goodman, 2012, Muscle fiber type-dependent differences in the regulation of protein synthesis, PLoS ONE, 7, e37890, 10.1371/journal.pone.0037890 · DOI · Paper page
  35. Schiro, 2011, Mutations in protein-binding hot-spots on the hub protein Smad3 differentially affect its protein interactions and Smad3-regulated gene expression, PLoS ONE, 6, e25021, 10.1371/journal.pone.0025021 · DOI
  36. Gomes, 2001, Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy, Proc Natl Acad Sci U S A, 98, 14440, 10.1073/pnas.251541198 · DOI · Paper page
  37. Foletta, 2011, The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy, Pflügers Arch, 461, 325, 10.1007/s00424-010-0919-9 · DOI · Paper page
  38. McFarlane, 2006, Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism, J Cell Physiol, 209, 501, 10.1002/jcp.20757 · DOI · Paper page
  39. Handschin, 2010, Regulation of skeletal muscle cell plasticity by the peroxisome proliferator-activated receptor γ coactivator 1α, J Recept Signal Transduct Res, 30, 376, 10.3109/10799891003641074 · DOI · Paper page
  40. Murphy, 2010, Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function, FASEB J, 24, 4433, 10.1096/fj.10-159608 · DOI · Paper page
  41. Samarakoon, 2013, TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities, Cell Signal, 25, 264, 10.1016/j.cellsig.2012.10.003 · DOI · Paper page
  42. Zhou, 2010, Targeting fibrosis in Duchenne muscular dystrophy, J Neuropathol Exp Neurol, 69, 771, 10.1097/NEN.0b013e3181e9a34b · DOI · Paper page
  43. Suelves, 2005, The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1), Front Biosci, 10, 2978, 10.2741/1754 · DOI · Paper page
  44. Dennler, 1998, Direct binding of Smad3 and Smad4 to critical TGF[beta]-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene, EMBO J, 17, 3091, 10.1093/emboj/17.11.3091 · DOI · Paper page
  45. Naderi, 2009, Plasminogen activator inhibitor type 1 up-regulation is associated with skeletal muscle atrophy and associated fibrosis, Am J Pathol, 175, 763, 10.2353/ajpath.2009.081009 · DOI
  46. Koh, 2005, Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration, Am J Physiol Cell Physiol, 289, C217, 10.1152/ajpcell.00555.2004 · DOI · Paper page
  47. van Rooij, 2008, Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis, Proc Natl Acad Sci U S A, 105, 13027, 10.1073/pnas.0805038105 · DOI · Paper page
  48. He, 2013, MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases, Biochimie, 95, 1355, 10.1016/j.biochi.2013.03.010 · DOI · Paper page
  49. Greco, 2009, Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia, FASEB J, 23, 3335, 10.1096/fj.08-128579 · DOI · Paper page
  50. Goldstein, 2010, Mechanisms of muscle weakness in muscular dystrophy, J Gen Physiol, 136, 29, 10.1085/jgp.201010436 · DOI
  51. Lipina, 2010, Mechanisms involved in the enhancement of mammalian target of rapamycin signalling and hypertrophy in skeletal muscle of myostatin-deficient mice, FEBS Lett, 584, 2403, 10.1016/j.febslet.2010.04.039 · DOI · Paper page
  52. Rena, 1999, Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B, J Biol Chem, 274, 17179, 10.1074/jbc.274.24.17179 · DOI · Paper page
  53. Zhao, 2005, Structure and function of the upstream promotor of the human Mafbx gene: The proximal upstream promotor modulates tissue-specificity, J Cell Biochem, 96, 209, 10.1002/jcb.20468 · DOI
  54. Gomis, 2006, A FoxO-Smad synexpression group in human keratinocytes, Proc Natl Acad Sci U S A, 103, 12747, 10.1073/pnas.0605333103 · DOI · Paper page
  55. Wang, 2010, Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the anti-diabetic drug, berberine, Diabetes, 59, 1879, 10.2337/db10-0207 · DOI
  56. Romanello, 2010, Mitochondrial biogenesis and fragmentation as regulators of muscle protein degradation, Curr Hypertens Rep, 12, 433, 10.1007/s11906-010-0157-8 · DOI
  57. Liu, 2013, Myostatin induces mitochondrial metabolic alteration and typical apoptosis in cancer cells, Cell Death Dis, 4, e494, 10.1038/cddis.2013.31 · DOI
  58. Chalhoub, 2009, 2009 PTEN and the PI3-kinase pathway in cancer, Annu Rev Pathol, 4, 127, 10.1146/annurev.pathol.4.110807.092311 · DOI · Paper page
  59. Ge, 2011, Smad3 signaling is required for satellite cell function and myogenic differentiation of myoblasts, Cell Res, 21, 1591, 10.1038/cr.2011.72 · DOI

Cited by

See all 138

Metadata

Authors
Goodman, C. A., McNally, R. M., Hoffmann, F. M., & Hornberger, T. A.
Venue
Molecular Endocrinology
Published
2013-11-01
Volume
27
Issue
11
Pages
1946-1957
ISSN
  • 0888-8809 (ISSN-L)
  • 1944-9917
OpenAlex
W2000066959
Cited by
138
References
24
FWCI
3.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.